Mark Sundrud, PhD
Professor of Medicine
Professor of Microbiology and Immunology
Principal Investigator, Dartmouth Health
Microbiology and Immunology
Ph.D., Vanderbilt University Medical Center (Microbiology & Immunology)
B.A., Concordia College (Biology, Psychology
Molecular and Cellular Biology Graduate Programs
Norris Cotton Cancer Center
Borwell Research Building, HB7999
1 Medical Center Drive
Lebanon NH 03756
Office: Borwell 630W
Intestinal immune regulation; gastrointestinal physiology; development and function of effector and regulatory T cells; bile acids; nuclear receptors; inflammatory bowel disease
Rotations and Thesis Projects
Nuclear receptor networks in intestinal T cell development and function; T cell redox metabolism; gut microbe-bile acid-T cell interplay'; region-specific immune regulatory networks in the intestine; immune and bile acid dysregulation in IBD; bile acid-directed IBD therapies.
NIH R01 5R01AI143821, “Determinants of bile acid-dependent T cell regulation in the intestine" (PI); 1 R01 AI164772-01, “Nuclear receptor control of T cell function in discrete intestinal microenvironments” (PI); 1 U01 AI163063-01, “Nuclear Receptor Networks in Mucosal Immune Regulation” (PI); 1 R21 AI154039-01A1, “Transcript-selective translational control of Th17 cell development and function” (PI)
A native of Minnesota, Dr. Sundrud received his Ph.D. in Cellular and Molecular Immunology from Vanderbilt University, and performed post-doctoral training at Harvard Medical School as an Irvington Institute fellow of the Cancer Research Institute (CRI). After his postdoc, Dr. Sundrud spent 3 years leading Discovery Biology research at Tempero Pharmaceuticals, a GSK-funded start-up biotech company located in Cambridge, MA. Dr. Sundrud was recruited to join the Faculty of The Scripps Research Institute’s Jupiter, Florida (Scripps Florida) campus as an Assistant Professor in 2013. He was promoted to Full Professor (with Tenure) in January 2022, and joined Dartmouth Health and Geisel School of Medicine at Dartmouth College in September 2022. Dr. Sundrud’s work focuses broadly on identifying, and ultimately manipulating, novel pathways underlying T cell-driven inflammatory diseases. His lab has been consistently funded by the National Institutes of Health (NIH) and the Crohn’s and Colitis Foundation (CCF) to interrogate novel mechanisms by which xenobiotic-sensing nuclear receptors and transporters mediate crosstalk between T cells and bile acids in the small intestine.
Dr. Sundrud is a passionate advocate for increasing diversity, equity and inclusion (DEI) in the life and biomedical sciences. He has worked in both formal and informal settings throughout his career to increase access to undergraduate research opportunities, particularly for low-income, rural, first-generation college and URM students. Dr. Sundrud's experience in both the Academic and Industry research sectors affords his students and trainees with unique perspectives on the skills and insights needed to pursue careers in either arena.
Development of a putative Zn(2+)-chelating but highly selective MMP-13 inhibitor.
Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy.
CAR directs T cell adaptation to bile acids in the small intestine.
Regulation of Intestinal Inflammation by Dietary Fats.
Genetic and pharmacological inhibition of the nuclear receptor RORα regulates T(H)17 driven inflammatory disorders.
Physiological expression and function of the MDR1 transporter in cytotoxic T lymphocytes.
Aminoacyl-tRNA synthetase inhibition activates a pathway that branches from the canonical amino acid response in mammalian cells.
Artificial microbiome heterogeneity spurs six practical action themes and examples to increase study power-driven reproducibility.
The Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile Acids.
Emerging roles of bile acids in mucosal immunity and inflammation.